Fundz

Fundz Deep Dive

Everything you need to win Hideo Makimura — in one platform.

Who to reach, what to say, and why now on Hideo Makimura — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Hideo Makimura — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Affinia Therapeutics Appoints Hideo Makimura, M.D., Ph.D. As Chief Medical Officer

PRIVATEFeb 05, 2025•over 1 year ago

Position

Chief Medical Officer

Company

Affinia Therapeutics

Hideo Makimura
WalthamBiotechnologyHealth Careresearch

Description

Affinia Therapeutics has appointed Hideo Makimura, MD, PhD as its Chief Medical Officer. Dr Makimura brings extensive leadership experience in early- and late-stage clinical research and development in the biopharmaceutical industry and academic research, as well as complementary clinical practice expertise as an endocrinologist. His appointment is a key step in progressing the lead investigational drug program, AFTX-201 in BAG3 dilated cardiomyopathy, toward an IND application later this year and building the pipeline of cardiovascular and neurologic programs.

Company Information

Company

Affinia Therapeutics

Location

43 Foundry Ave

Waltham, Massachusetts, United States

About

Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates in cardiovascular and neurological diseases leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Affinia Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.